A prospective, open-label, multi-centre phase II study to investigate the safety and efficacy of a combination therapy with nivolumab, ipilimumab and bevacizumab together with 2 cycles of induction chemotherapy in patients with non-squamosisNSCLC with brain metastases (CA209-7WF/Break B5)

Heudobler, Daniel and Schulz, Christian and Illerhaus, G. and Janning, M. and Griesinger, F. and Lüke, Florian and Herr, Wolfgang and Pukrop, Tobias (2022) A prospective, open-label, multi-centre phase II study to investigate the safety and efficacy of a combination therapy with nivolumab, ipilimumab and bevacizumab together with 2 cycles of induction chemotherapy in patients with non-squamosisNSCLC with brain metastases (CA209-7WF/Break B5). In: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien.

Full text not available from this repository.
Item Type: Conference or Workshop Item (Poster)
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Medicine > Lehrstuhl für Innere Medizin II
Depositing User: Petra Gürster
Date Deposited: 11 Oct 2023 08:32
Last Modified: 11 Oct 2023 08:32
URI: https://pred.uni-regensburg.de/id/eprint/57433

Actions (login required)

View Item View Item
pred is powered by EPrints 3.4 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.